The Institute for Technology Assessment’s (ITA) mission is to conduct health outcomes research to guide the development, evaluation, and utilization of medical technologies that improve the quality and cost-effectiveness of medical care

image of people sitting around a table.

Who are we?

We are physicians and methodologic experts from diverse fields and we find where healthcare is valuable. Our research aims to optimize disease treatment and prevention, quality of life, and cost-effectiveness of care. The ITA includes individuals with training and expertise in the core disciplines of biostatistics, epidemiology, economics, decision science, health-related quality of life measurement, outcomes analysis, and health care policy.

screen image of computer code

What do we do at the ITA?

We synthesize currently available data from myriad sources to develop mathematical models that answer big-ticket public health questions when clinical trials are not feasible

We work in a collaborative team

The ITA is known for outcomes research in cancer (colorectal, lung, esophageal & thyroid) and several new research projects were initiated in the last five years that aim at informing policies to address the opioid epidemic (in collaboration with the Food and Drug Administration), global hepatitis C elimination (in collaboration with the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO)), and more recently, COVID-19 mitigation response in the U.S.

Workshops at the ITA

Check back soon for more information on future workshop offerings.

Upcoming Seminar at the ITA (SITA)

Please join the MGH Institute for Technology Assessment Tuesday, November 12th, 12:00 – 1:00 PM EST via Zoom

Presentation by Dr. Reza Yaesoubi, PhD

Talk Title: TBD

Please note this talk will be recorded.

Send email to to receive Zoom information

Read more


ITA in the News

Costs of Alcohol-Associated Liver Disease Will Double by 2040

Gastroenterology & Endoscopy News | Gina Shaw Rising rates of alcohol-associated liver disease will lead to major increases in costs to the healthcare system ...

Excited about new diet drug? This procedure seems better choice.

The Harvard Gazette | Alvin Powell, Staff Writer | May 6, 2024 Study finds minimally invasive treatment more cost-effective over time, brings ...

Congress can eradicate hepatitis C and reduce the deficit at the same time

STAT - By Neeraj Sood and Jagpreet Chhatwal July 14, 2023 Congress faces a historic opportunity to stamp out a disease that ...